Health and Healthcare
Why Credit Suisse's Neutral Rating on Teva Almost Sounds Like a Buy Rating
Published:
Last Updated:
When investors hear that a company is initiated in coverage with a Neutral rating, they generally interpret this to mean Hold. Some might even say that it means Sell. Things are different in the Credit Suisse ratings system because it uses a relative peer-reference base rather than a market performance-based expectation. It turns out that a new Neutral rating on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) from Credit Suisse actually comes with significant upside.
One thing investors need to consider is that as bull markets continue, analysts issuing Buy or Outperform ratings for large cap stocks generally come with implied upside of 8% to 15%. Teva was given an implied upside north of 13% here, if you include its 2.5% dividend yield.
Credit Suisse’s price target of $60 compares to a prior close of $54.20, but the weakness in the stock market on Wednesday and the unenthusiastic Neutral rating by the sound of it had Teva’s shares down another 1.1% to $53.60. From that level, the implied upside is almost 15%.
So, what is it that Credit Suisse sees happening with Teva for close to 15% upside but only a Neutral rating? Vamil Divan and Anamaria Sudarov made the Neutral recommendation on Wednesday.
Furthermore, regarding Teva’s specialty pharma business, questions remain about the longevity of Copaxone. Credit Suisse pointed out that numerous legal decisions are due in the next 12 to 18 months that will determine the franchise’s outlook. The report said:
The Street does now seem to be factoring in a near-worst case scenario for Copaxone, but we also look for more evidence on TEVA’s ability to successfully expand beyond Copaxone and become a more diversified specialty pharma company, with our greatest excitement centered around TEV-48125 (anti-CGRP for migraines).
Several positives were mentioned:
The key investment risks were listed as follows:
Catalysts for Teva include the earnings report due on May 9 and the Copaxone IPR hearing on May 12. Its SD-809 Huntington’s Disease target has a PDUFA in late May, and the coming closure of Allergan’s generics acquisition is expected in June.
Credit Suisse’s team has based its $60 target price with a 75% relative valuation and 25% from a discounted cash flow model. It is also based on an 11.0 times the Credit Suisse 2017 EPS estimate of $5.97 (and then discounted back to 2016) for a net level of $5.48 per share. The firm’s cash flows are modeled through 2025 with a 9% weighted average cost of capital and a 1% terminal growth.
So, how does this all stand up to the rest of the pack? Trading at $53.60, Teva has a consensus analyst price target of $74.60 and a 52-week range of $52.62 to $72.31.
Be advised that Teva Pharmaceutical is one of the 10 stocks to own for the next decade from 24/7 Wall St.
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.